Frontier Medicines is dedicated to advancing science to defeat disease, focusing on covalent drug discovery powered by chemoproteomics and AI. The company is unlocking the proteome to develop a differentiated pipeline of small-molecule drugs against previously undruggable targets.
We're tracking Frontier Medicines's market expansion
How Frontier Medicines's international expansion compares to its competitors
Frontier MedicinesYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Frontier MedicinesYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
LG Chem signed exclusive global licensing agreement with Frontier Medicines for FMC-220, targeting p53 Y220C mutation in ovarian cancer. Phase 1 trials planned in US and Korea this year.
Be the first to find verified contacts at Frontier Medicines
Quick answers about Frontier Medicines's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
